These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2016-004259-59||Multi-center, single-arm, open-label study in patients with Insomnia Disorder to validate the Insomnia Daytime Symptoms and Impacts Questionnaire™ (IDSIQ™)||2017-06-12||due-trials|
|Completed, report not yet due||2017-000494-36||A Phase 2a, multi-center, single-blind, within-subject, placebo-controlled study to assess the pharmacodynamics of ACT-709478 in subjects with photosensitive epilepsy||2018-04-25||not-yet-due|
|Completed, report not yet due||2017-003332-36||A multi-center, double-blind, randomized, placebo-controlled study to assess the pharmacodynamics, pharmacokinetics, tolerability, and safety of a single subcutaneous injection of ACT-246475 in adults...||2018-09-18||not-yet-due|
|Ongoing||2017-003369-85||A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease.||not-yet-due|
|Ongoing||2017-004393-33||Multi-center, blinded, randomized, parallel-group, Phase 3 study with aprocitentan in subjects with Resistant Hypertension (RHT)||not-yet-due|
|Ongoing||2017-004642-20||Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography study to assess the efficacy and safety of ACT-541468 in adult and elderly subjects with insomnia disorder||not-yet-due|
|Ongoing||2017-004643-20||Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography study to assess the efficacy and safety of ACT-541468 in adult and elderly subjects with insomnia disorder||not-yet-due|
|Ongoing||2017-004644-38||Multi-center, double-blind, parallel-group, randomized, placebo-controlled, three doses, 40-week extension to studies ID-078A301 and ID-078A302 to assess the long term safety and tolerability of ACT-5...||not-yet-due|
|Other||2018-000241-39||A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to assess the efficacy and safety of clazosentan in preventing clinical deterioration due to de...||not-yet-due|
|Ongoing||2018-000851-42||A randomized, double-blind, placebo-controlled, single-center, 12-week study to evaluate the effect of ACT-774312 in subjects with bilateral nasal polyposis||not-yet-due|
|Ongoing||2018-001808-11||A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic...||not-yet-due|
|Ongoing||2018-002210-12||A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease||not-yet-due|